Nexviazyme Injection, Powder, Lyophilized, For Solution
Product Images NDC 58468-0426

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Nexviazyme (NDC 58468-0426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genzyme Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Nexviazyme 01)

This appears to be a chart comparing the effectiveness of two treatments, Nexviazyme and Alglucosidase alfa, for an undisclosed medical condition, over a period of nine weeks. The chart shows the number of patients who underwent each treatment, with Nexviazyme having a consistently higher number of patients throughout the period. The percentage changes in effectiveness for both treatments are also noted, with an increase of 2.89% for Nexviazyme and 0.46% for Alglucosidase alfa.*

FDA Label Image

Figure 2 (Nexviazyme 02)

This appears to be a table presenting the number of patients treated with two different medications (Nexviazyme and Alglucosidase alfa) at different time points (Baseline, Week 13, Week 25, Week 37, and Week 49). The number of patients receiving Nexviazyme ranged from 48 to 51 while the number of patients receiving Alglucosidase alfa ranged from 43 to 49. However, without additional context, the purpose or significance of this data is not clear.*

FDA Label Image

Principal Display Panel (100 mg Vial Carton)

This is a description of a medication called Nexviazyme~ used for intravenous infusion. The medication comes in a single-dose vial with a concentration of 100mg/10mL after reconstitution with sterile water or injection. The active ingredients are glycine, histidine, and alglucosdas aliengpt. The medication is stored refrigerated at 2°C to 8°C and can be stored up to 24 hours after reconstitution. The medication is manufactured by Genzyme Corporation in Cambridge, MA, and has a US License No. 1596. Discard any unused portion of the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.